ABSTRACT
Introduction: worldwide, approximately 180 million people are living with CHC, which corresponds to a global prevalence of 1.1% and millions more are newly infected each year. Annually, 700.000 people die from HCV-related complications, including cirrhosis and hepatocellular carcinoma [HCC]
Aim of the work: the present study investigated the dynamics of change in various HCV antibodies in patients with CHC who achieved SVR after DAAs
Methodology: this was a prospective case-control study that was conducted on 150 patients. They were categorized into three main groups: Group I: included 100 patients with chronic HCV infection as diagnosed by SRT-PCR. They were submitted to treatment with DAAs for 12 weeks. Group II [positive control group]: Included 25 patients who presented with CHC infection as diagnosed by positive anti-HCV IgG antibodies and positive HCV SRT-PCR, but either refuse or postpone HCV therapy or the treatment of HCV itself was contraindicated. Group III [negative control group]: included 25 patients, apparently healthy individuals who test positive for anti-HCV IgG antibodies, but negative HCV SRT-PCR. HCV IgG Ab titers was assessed by commercially available third-generation enzyme-linked immunosorbent assay [ELISA] at base line, end of treatment and then at the 24th week [i.e. 12 weeks after the end of treatment]
Results: as regard HCVAb, it showed a significant statistical difference [p-value < 0.001] between titer results at baselin12th week and 24th week in patients group I; as HCV Ab titers were 3.3 +/- 0.2 mg/dl at baseline and declined to 2.7 +/- 0.2 at 12th week and 2.4 +/- 0.3 at 24th week. But, there was no statistical significant difference [p-value > 0.05] between HCV Ab titer results at baseline, 12th week and 24th week in the studied positive control patients group II as HCV Ab titers were 3.1 +/- 0.2 at baseline, 3.2 +/- 0.2 at 12th week and [3.2+/- 0.1] at 24th week week. Also, there was no statistical significant difference [p-value > 0.05] between HCV Ab titer results at baseline, 12th week and24th week in studied negative control patients group III as HCV Ab titers were 1.22 +/- 08 at baseline, [1.23+/-0.08] at 12th week and 1.24+/- 0.07 at 24th week
Conclusion: HCV antibody titer appeared to continue to decrease after eradication of HCV by DAAs therapy
ABSTRACT
Background: hepatitis C Virus [HCV] has complex interactions with human lipid metabolism leading to down regulation of cholesterol level. Interferon [INF] therapy has been shown to decrease cholesterol even further during treatment .With the availability of direct acting antiviral agents [DAAs] the effect of suppressing HCV on lipid metabolism warrantes re-evaluation
Aim of the work : goal of our study was evaluation the changes in lipid profile after treatment of chronic HCV infection with oral antiviral medications in diabetic patients
Methods: this prospective study conducted on 90 HCV infected patients, all patients received Sofosbuvir [SOF] and Daclatasvir [DCV] as a dual therapy for 3 months. They were divided according to the presence or absence of diabetes mellitus [DM] and hyperlipidemia into three main groups; Group I: included 30 diabetic hyperlipidemic patients, Group II: included 30 non-diabetic hyperlipidemic patients, Group III: included 30 non-diabetic non- dyslipidemia patients.Changes of lipid profile on treatment with DAAs were assessed by checking fasting lipid profile at base line, then at end of treatment, and finally 3 months after treatment
Results: there was a statistically significant increase in total cholesterol level [TCHOL] which was maintained after the end of therapy. Changes in TCHOL were driven by changes in low-density lipo-protein [LDL] cholesterol, whereas high-density lipo-protien [HDL] cholesterol and very low-density lipo-protein [VLDL] cholesterol showed no significant changes. There were also no significant changes in tryglyceride [TG] level on treatment
Conclusion: eliminating HCV with DAAs increased TCHOL but had no effect on TG level